20 July 2020

Metastatic prostate cancer hijacks DNA program for embryonic development

Elize Brolsma

(Press release via Netherlands Cancer Institute)

Metastatic prostate cancer cells that spread throughout the patient’s body reactivate a DNA program responsible for fetal prostatic development, new research shows. Cancer researchers led by Oncode Investigator Wilbert Zwart (NKI) and Matthew Freedman of the Harvard Dana-Farber Cancer Institute in Boston, demonstrated this process in tissue samples taken from hundreds of surgically removed prostate tumors.

This reactivation of an embryonic DNA program during metastasis has never before been documented in cancer research.

The researchers have published their findings on July 20, 2020, in the scientific journal Nature Genetics. Yanyun Zhu, PhD researcher at the Netherlands Cancer Institute, is one of the leading researchers.

Back in time
“Once prostate cancer metastasizes, the tumor cell travels back in time to the embryonic state, when the prostate develops in utero,” says research leader Wilbert Zwart, who specializes in hormone-sensitive cancers, such as prostate cancer.

During fetal development, the formation of the prostate is facilitated by several activated DNA programs in specific locations. Once the prostate is “done”, these programs are turned off. And they remain off, even in patients with prostate tumors. Until the tumor metastasizes.

Molecular footprint
This “organ development” DNA program in prostate cells appears to retain a memory of its previous activity. As fellow research leader Matthew Freedman states, the activity seems to have left behind some sort of molecular footprint. The tumor “abuses” this slumbering memory when spreading throughout the body.

All metastatic prostate tumors
Wilbert Zwart: “This turned out to be the case in every metastasis we studied. Every tumor is unique, but all metastatic tumors shared this one trait: the metastatic tumor cells reactivated DNA that has been inactive since fetal development, in order to metastasize. This is a tremendously valuable discovery! As a potential follow-up question, we could consider whether this process is unique to prostate cancer, or whether other tumor types also use this embryogenesis-specific program to metastasize.” The researchers hope that this new knowledge will lead to the development of new treatment options.

Cooperation of many patients
Among the researchers involved in this study were medical specialists André Bergman and Henk van der Poel of the Netherlands Cancer Institute, both specialized in prostate cancer. Metastases often make cancer incurable. Bergman: “Thanks to this important step in our understanding of the development of metastatic cancer, we are one step closer to potential preventative measures. We owe our discovery to the many patients who chose to cooperate with our research, and the development of new treatment options.”

Regulatory proteins
Zwart: “During our research, we found multiple proteins that are involved in the DNA programs for organ development that appear to be hijacked by metastatic prostate cancer. By using drugs to inhibit these proteins, we want to try and block tumor metastasis. We are currently initiating these experiments at our lab, and hope to eventually translate our findings into medical practice.”

In order to conduct their research, the researchers from Amsterdam and Boston compiled the world’s biggest database of DNA regulating (“epigenetic”) processes in healthy prostate tissue and tumor tissue. They analyzed DNA regulation in hundreds of surgically removed prostate samples showing the transition between healthy prostate tissue and cancer, and between non-metastatic prostate cancer and metastatic tumors. This led to the discovery of the patterns that lie at the root of metastases.

Microscopic image of prostate cancer that has spread to a patient’s lymph node. Copyright: AVL

Other News

Kops website
New biosensor measures activity of control enzyme MPS1
Researchers from the group of Oncode Investigator Geert Kops (Hubrecht Institute) have developed a biosensor that can precisely depict the activity of the MPS1 enzyme in living cells. MPS1 is responsible for accurate distribution of DNA during cell division; errors in this process can lead to cancer. Using the new biosensor, the researchers discovered that the MPS1 enzyme is significantly less active in colorectal cancer cells. The results were published in the scientific journal Current Biology on the 3rd of September.
Pre-existing immune-resistant cancer cells identified in melanoma
Researchers at the Netherlands Cancer Institute, led by Oncode Investigator Daniel Peeper with Julia Boshuizen as first author, have discovered a cluster of tumor cells that are refractory to immunotherapy and that exists even prior to treatment. This finding, which was published in the scientific journal Nature Communications, may lead to new therapies that eliminate cancer more effectively.


Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations. At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
11 impact value 1
Convey impact, get funding
In order to give our community hands-on advice on how to improve their grant writing, we hosted a 90- minute interactive webinar: Get Funding: Convey the impact of your science.